| |  Online-Ressource |
|---|
| Verfasst von: | Brenner, Thorsten [VerfasserIn]  |
|---|
| | Skarabis, Annabell [VerfasserIn] |
|---|
| | Stevens, Philip [VerfasserIn] |
|---|
| | Axnick, Jennifer [VerfasserIn] |
|---|
| | Haug, Peter [VerfasserIn] |
|---|
| | Grumaz, Silke [VerfasserIn] |
|---|
| | Bruckner, Thomas [VerfasserIn] |
|---|
| | Luntz, Steffen P. [VerfasserIn] |
|---|
| | Witzke, Oliver [VerfasserIn] |
|---|
| | Pletz, Mathias W. [VerfasserIn] |
|---|
| | Ruprecht, Thomas M. [VerfasserIn] |
|---|
| | Marschall, Ursula [VerfasserIn] |
|---|
| | Altin, Sibel [VerfasserIn] |
|---|
| | Greiner, Wolfgang [VerfasserIn] |
|---|
| | Berger, Marc Moritz [VerfasserIn] |
|---|
| Titel: | Optimization of sepsis therapy based on patient-specific digital precision diagnostics using next generation sequencing (DigiSep-Trial) |
|---|
| Titelzusatz: | study protocol for a randomized, controlled, interventional, open-label, multicenter trial |
|---|
| Verf.angabe: | Thorsten Brenner, Annabell Skarabis, Philip Stevens, Jennifer Axnick, Peter Haug, Silke Grumaz, Thomas Bruckner, Steffen Luntz, Oliver Witzke, Mathias W. Pletz, Thomas M. Ruprecht, Ursula Marschall, Sibel Altin, Wolfgang Greiner, and Marc Moritz Berger for the TIFOnet Critical Care Trials Group |
|---|
| E-Jahr: | 2021 |
|---|
| Jahr: | 18 October 2021 |
|---|
| Umfang: | 12 S. |
|---|
| Fussnoten: | Gesehen am 30.12.2021 |
|---|
| Titel Quelle: | Enthalten in: Trials |
|---|
| Ort Quelle: | London : BioMed Central, 2000 |
|---|
| Jahr Quelle: | 2021 |
|---|
| Band/Heft Quelle: | 22(2021), Artikel-ID 714, Seite 1-12 |
|---|
| ISSN Quelle: | 1468-6694 |
|---|
| | 1745-6215 |
|---|
| Abstract: | Sepsis is triggered by an infection and represents one of the greatest challenges of modern intensive care medicine. With regard to a targeted antimicrobial treatment strategy, the earliest possible pathogen detection is of crucial importance. Until now, culture-based detection methods represent the diagnostic gold standard, although they are characterized by numerous limitations. Culture-independent molecular diagnostic procedures represent a promising alternative. In particular, the plasmatic detection of circulating, cell-free DNA by next-generation sequencing (NGS) has shown to be suitable for identifying disease-causing pathogens in patients with bloodstream infections. |
|---|
| DOI: | doi:10.1186/s13063-021-05667-x |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1186/s13063-021-05667-x |
|---|
| | DOI: https://doi.org/10.1186/s13063-021-05667-x |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Bacteremia |
|---|
| | Blood culture |
|---|
| | Desirability of Outcome Ranking/Response Adjusted for Duration of Antibiotic Risk (DOOR/RADAR) score |
|---|
| | Digital precision diagnostics |
|---|
| | Next generation sequencing |
|---|
| | Sepsis |
|---|
| K10plus-PPN: | 178443423X |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Optimization of sepsis therapy based on patient-specific digital precision diagnostics using next generation sequencing (DigiSep-Trial) / Brenner, Thorsten [VerfasserIn]; 18 October 2021 (Online-Ressource)
